US20150118237A1 - Anti-human cd69 antibody, and use thereof for medical purposes - Google Patents

Anti-human cd69 antibody, and use thereof for medical purposes Download PDF

Info

Publication number
US20150118237A1
US20150118237A1 US14/396,521 US201314396521A US2015118237A1 US 20150118237 A1 US20150118237 A1 US 20150118237A1 US 201314396521 A US201314396521 A US 201314396521A US 2015118237 A1 US2015118237 A1 US 2015118237A1
Authority
US
United States
Prior art keywords
seq
antibody
amino acid
acid sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/396,521
Other languages
English (en)
Inventor
Kanehisa KOJOH
Akira Miyakoshi
Shizue Katoh
Kumiko TSUIHIJI
Yuki HAYAMI
Mikiko NAKAMURA
Toshinori Nakayama
Chiaki Iwamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
Genefrontier Corp
Original Assignee
Chiba University NUC
Genefrontier Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC, Genefrontier Corp filed Critical Chiba University NUC
Assigned to NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, GENEFRONTIER CORPORATION reassignment NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IWAMURA, Chiaki, HAYAMI, Yuki, KOJOH, KANEHISA, MIYAKOSHI, AKIRA, NAKAMURA, MIKIKO, NAKAYAMA, TOSHINORI, TSUIHIJI, Kumiko, KATOH, SHIZUE
Publication of US20150118237A1 publication Critical patent/US20150118237A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to an anti-human CD69 antibody, and pharmaceutical use thereof.
  • CD69 is a type II transmembrane protein belonging to the C-type lectin family. Since the expression of CD69 increases within a few hours after stimulation of T cells and B cells, it is widely used as an early activation marker molecule to be an index of lymphocyte activation (non-patent document 1). In addition, the expression is also observed in T cells under selection during differentiation in thymus (non-patent documents 2 and 3). While CD69 is assumed to have a function as a coreceptor to potentiate signal transduction from an antigen receptor, the detail is unknown. Its ligand has not been identified to date. It is constitutively expressed in platelet, and the expression is also observed in activated neutrophils, eosinophils and the like.
  • CD69 on the neutrophil plays an important role in the onset of arthritis (non-patent document 4). Furthermore, it has been reported that CD69 controls allergic airway inflammation, and an antibody to mouse CD69 inhibits allergic airway inflammation (non-patent document 5). It has also been reported that COPD induced by cigarette smoke and lung fibrogenesis induced by bleomycin are attenuated in CD69 deficient mouse (non-patent document 6 and 7). Therefore, application of an antibody to CD69 to the prophylaxis or treatment of such allergic diseases and inflammatory diseases is expected.
  • the phage display method is one of the display techniques that have realized an in vitro high-speed selection by forming a one-to-one correspondence in the form of phage particle between a functional peptide or protein and a DNA encoding same.
  • This phage display method has been applied to antibody selection, and antibodies obtained by this method have been developed as medicaments (non-patent document 8).
  • a method of obtaining a specific antibody by combining a human artificial antibody library and a phage display method has been established, and such methods have been practicalized by plural companies, as evidenced by HuCAL (Human Combinatorial Antibody Library) of MorphoSys.
  • An object of the present invention is to provide an anti-human CD69 antibody applicable to the prophylaxis or treatment of allergic diseases and inflammatory diseases.
  • the present inventors first produced an anti-CD69 antibody that binds to both human CD69 and mouse CD69.
  • they intensively studied a method of evaluating a pharmacological effect of anti-human CD69 antibody in vivo.
  • they have succeeded in reproducing an allergic reaction in mouse, which is mediated by Th2 cells that express human CD69, by forcibly expressing human CD69 in Th2 cells of CD69 deficient mouse immunized with a particular antigen, and returning the Th2 cells into the body of the mouse.
  • They have produced a plurality of anti-human CD69 antibodies by HuCAL, and evaluated the effect on the allergic reaction by using the aforementioned mouse.
  • the present invention relates to the following.
  • An antibody that specifically binds to human CD69 has an activity to suppress allergic inflammation, and comprises a light chain variable region and a heavy chain variable region, wherein (3) the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 2 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 4, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 5 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 6; (4) the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 13, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 14 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 15, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, CDR2 comprising the amino acid sequence shown in
  • a pharmaceutical composition comprising the antibody of any of [1]-[9].
  • a prophylactic or therapeutic agent for an allergic disease or inflammatory disease comprising the antibody of any of [1]-[9].
  • a polynucleotide encoding the antibody of any of [1]-[9].
  • a vector comprising the polynucleotide of [12].
  • a transformant comprising the vector of [13].
  • a non-human mammal comprising transferred Th2 cells of CD69 deficient non-human mammal immunized with a particular antigen, wherein the Th2 cells express human CD69.
  • the non-human mammal of [15] wherein the non-human mammal is a mouse.
  • a method for the prophylaxis or treatment of an allergic disease or inflammatory disease in a mammal comprising administering an effective amount of the antibody of any of [1]-[9] to said mammal.
  • an anti-human CD69 antibody applicable to the prophylaxis or treatment of allergic diseases and inflammatory diseases is provided.
  • an animal model permitting in vivo evaluation of a pharmacological effect of an anti-human CD69 antibody can be provided.
  • FIG. 1 shows evaluation of binding to human CD69 and mouse CD69 by cell staining.
  • FIG. 2 shows analysis of human CD69 expression by flow cytometry.
  • FIG. 3 shows the effect of various anti-human CD69 antibodies on alveolar leukocyte infiltration.
  • FIG. 4 confirms cross-reactivity of various anti-human CD69 antibodies with mouse CD69 and human CD69 by flow cytometry.
  • FIG. 5 shows the effect of various anti-human CD69 antibodies against alveolar leukocyte infiltration.
  • FIG. 6 shows alignment of the amino acid sequences of mouse CD69 (upper sequence) and human CD69 (lower sequence).
  • the present invention provides an antibody having a specific binding activity to human CD69, and an activity to suppress allergic inflammation.
  • CD69 is a known TYPE II membrane protein, and the amino acid sequence thereof and the cDNA sequence thereof are also known.
  • a representative amino acid sequence of human CD69 is shown in SEQ ID NO: 30
  • a representative cDNA sequence of human CD69 is shown in SEQ ID NO: 29
  • a representative amino acid sequence of mouse CD69 is shown in SEQ ID NO: 32
  • a representative cDNA sequence of mouse CD69 is shown in SEQ ID NO: 31.
  • the antibody of the present invention has a specific binding activity to an extracellular domain of human CD69.
  • the extracellular domain of human CD69 corresponds to the region of 62-199 in the amino acid sequence shown by SEQ ID NO: 30, and the extracellular domain of mouse CD69 corresponds to the region of 62-199 in the amino acid sequence shown by SEQ ID NO: 32.
  • the “human CD69” means that the amino acid sequence or nucleic acid sequence of CD69 has an amino acid sequence or nucleic acid sequence which is the same as or substantially the same as the amino acid sequence or nucleotide sequence of CD69 naturally expressed in human.
  • the “substantially the same” means that the amino acid sequence or nucleic acid sequence of interest has 70% or more (preferably 80% or more, more preferably 90% or more, further preferably 95% or more, most preferably 99% or more) identity with the amino acid sequence or nucleic acid sequence of a particular CD69 naturally expressed in human, and has the function of the particular human CD69.
  • Biological species other than human, proteins other than CD69, gene and fragments thereof are also interpreted in the same manner.
  • the “specific binding” of an antibody to antigen X means that the K D value of the binding affinity of an antibody to antigen X in an antigen-antibody reaction is not more than 1 ⁇ 10 ⁇ 7 M.
  • the N D value relating to the binding affinity of the antibody of the present invention to human CD69 is calculated according to the principle described in Immunoassays (OXFORD UNIVERSITY PRESS, 2000) using a scatchard plot method.
  • An antibody is incubated with various concentrations of antigen (extracellular domain of human CD69) at room temperature for 2 hr until equilibrium, and the amount of free antibody present in the incubation solutions is measured by the ELISA method.
  • the binding constant and dissociation constant (K D value) are determined based on the changes in the amount of free antibody in each equilibrated sample.
  • the antibody concentration during equilibration reaction is to be 0.015 ⁇ g/ml, and an ELISA plate for the measurement of the amount of free antibody is to be immobilized with the antigen at 1 ⁇ g/ml.
  • the K D value relating to the binding affinity of the antibody of the present invention to human CD69 is not more than 5 ⁇ 10 ⁇ 8 M.
  • the antibody of the present invention has an activity to suppress allergic inflammations.
  • Allergic inflammation refers to inflammations characterized by selective accumulation of mononuclear cells in the target tissue, which occurs in association with allergic reactions. Mononuclear cell encompasses Th2 cells, eosinophils, basophils and mast cells. Whether or not an antibody has an activity to suppress allergic inflammations can be confirmed by evaluating whether or not it suppresses an allergic reaction (e.g., leukocyte infiltration) induced by exposing the below-mentioned non-human mammal of the present invention to an antigen.
  • an allergic reaction e.g., leukocyte infiltration
  • the “antibody” is used as one encompassing a full-length antibody and any antigen-binding fragment (i.e., “antigen-binding portion”) thereof or a single chain thereof.
  • the “antibody” refers to a glycoprotein containing at least two heavy chains (H) and two light chains (L), which are linked by a disulfide bond, or an antigen-binding portion thereof.
  • Each heavy chain is constituted by a heavy chain variable region (to be abbreviated as V H herein) and a heavy chain constant region.
  • the heavy chain constant region is constituted by 3 domains of C H 1, C H 2 and C H 3.
  • Each light chain is constituted by a light chain variable region (to be abbreviated as V L herein) and a light chain constant region.
  • the light chain constant region is constituted by a single domain C L .
  • V H and V L regions are further subdivided into regions with higher variability called complementarity determining regions (CDRs), which contain more highly conservative regions called framework regions (FRs) scattered therein.
  • CDRs complementarity determining regions
  • FRs framework regions scattered therein.
  • Each V H and V L is constituted by 3 CDRs and 4 FRs, which are aligned in the following order, i.e., FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
  • the variable regions of said heavy chain and light chain contain binding domains that interact with an antigen.
  • the constant region of an antibody can mediate the binding of immunoglobulin to host tissues or factors, including various cells (e.g., effector cells
  • the “antigen-binding portion” of an antibody is used to refer to one or more fragments of an antibody retaining an ability to specifically bind to an antigen (e.g., human CD69). It has been clarified that the antigen binding function of an antibody is performed by a fragment of a full-length antibody.
  • binding fragment included in the term “antigen binding portion” of an antibody examples include (i) Fab fragment, a monovalent fragment constituted by V L , V H , C L and C H1 domains, (ii) F(ab′) 2 fragment, a divalent fragment containing two Fab fragments linked by disulfide bond in the hinge region, (iii) Fab′ fragment, an inherent Fab having a hinge region portion (see FUNDAMENTAL IMMUNOLOGY, Paul ed., 3. sup. rd ed.
  • V L and V H which are the two domains of Fv fragment, are encoded by different genes, they can be linked by a synthetic linker to produce a single protein chain from them by recombinant techniques, wherein, in this chain, V L and V H regions pair with each other to form a monovalent molecule (known as a single chain Fv (scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883).
  • scFv single chain Fv
  • Such single chain antibody is also encompassed in the “antigen-binding portion” of an antibody.
  • Such antibody fragments are obtained by those of ordinary skill in the art by known conventional techniques, and screened for usefulness in the same manner as with unmodified antibody.
  • the antibody of the present invention is preferably a monoclonal antibody.
  • the “monoclonal antibody” refers to a preparation of an antibody molecule of a single molecule composition.
  • the monoclonal antibody composition shows single binding-specificity and affinity for a particular portion of an antigen called epitope.
  • the antibody of the present invention is preferably a human antibody.
  • the “human antibody” refers to an antibody having variable regions derived from a human germline immunoglobulin sequence in both the framework and CDR regions. Furthermore, when an antibody contains a constant region, the constant region also derives from a human germline immunoglobulin sequence.
  • the “human antibody” also encompasses even an embodiment including an amino acid residue not encoded by a human germline immunoglobulin sequence (e.g., mutation introduced by random or site-directed mutagenesis in vitro or somatic mutation in vivo). In the present specification, however, the term of the “human antibody” is not intended to include an antibody wherein a CDR sequence derived from the germline of an animal species other than human, such as mouse, is fused on the human framework sequence.
  • the human antibody encompasses a “reconstituted human antibody”.
  • the reconstituted human antibody refers to a modified antibody wherein at least one CDR contained in the first human donor antibody is used in the second human acceptor antibody, instead of CDR of the second human acceptor antibody. Preferably, all 6 CDRs are substituted. More preferably, the whole antigen binding region (e.g., Fv, Fab or F(ab′)2) of the first human donor antibody is used instead of the corresponding region in the second human acceptor antibody. More preferably, the Fab region of the first human donor antibody is operably linked to an appropriate constant region of the second human acceptor antibody to form a full-length antibody.
  • the reconstituted human antibody can be produced by conventional gene recombinant techniques disclosed in, for example, EP125023, WO96/02576, non-patent document 8 and the like.
  • a DNA sequence designed to link a desired CDR in a donor human antibody and a desired framework region (FR) in an acceptor human antibody is synthesized by PCR method using, as primers, several oligonucleotides produced to have a region overlapping with the terminus regions of both CDR and FR (see the method described in WO98/13388).
  • the obtained DNA is linked to a DNA encoding a human antibody constant region or a human antibody constant region mutant, which is incorporated into a expression vector and the vector is introduced into a host to allow for production, whereby a reconstituted human antibody can be obtained (see EP125023, WO96/02576).
  • the human antibody encompasses an “artificial human antibody”.
  • the artificial human antibody can be produced by conventional gene recombinant techniques disclosed in, for example, non-patent document 8 and the like.
  • the antibody of the present invention also includes a fusion protein wherein the aforementioned antibody and other peptide or protein are fused.
  • the production method of a fusion protein includes linking a polynucleotide encoding the antibody of the present invention and a polynucleotide encoding other peptide or polypeptide to match the frame, introducing same into an expression vector, and allowing expression thereof in a host, and techniques known to those of ordinary skill in the art can be used.
  • known peptides such as FLAG (Hopp, T. P.
  • 6 ⁇ His consisting of six His (histidine) residues, 10 ⁇ His, human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40T antigen fragment, lck tag, ⁇ -tubulin fragment, B-tag, Protein C fragment and the like can be used.
  • other polypeptide to be fused with the antibody of the present invention include GST (glutathione-S-transferase), HA (influenza hemagglutinin), immunoglobulin constant region, ⁇ -galactosidase, MBP (maltose binding protein) and the like.
  • a commercially available polynucleotide encoding such peptide or polypeptide is fused with a polynucleotide encoding the antibody of the present invention, and a fusion polynucleotide prepared thereby is expressed, whereby a fusion polypeptide can be prepared.
  • the antibody of the present invention may be a conjugate antibody bound with various molecules, for example, polymer substances such as polyethylene glycol (PEG), hyaluronic acid and the like, radioactive substance, fluorescent substance, luminescence substance, enzyme, toxin and the like.
  • PEG polyethylene glycol
  • Such conjugate antibody can be obtained by chemically modifying the obtained antibody.
  • the modification method of antibody has already been established in this field (e.g., U.S. Pat. No. 5,057,313, U.S. Pat. No. 5,156,840).
  • the antibody of the present invention is preferably isolated or purified. Being “isolated or purified” means that an operation to remove components other than the component of interest has been applied to the state of natural presence.
  • the purity of the isolated or purified antibody of the present invention is generally 50% or more, preferably 70% or more, more preferably 90% or more, most preferably 95% or more (e.g., substantially 100%).
  • the antibody of the present invention has cross-reactivity with mouse CD69 (preferably extracellular domain of mouse CD69).
  • the “cross-reactivity” means that an antibody that specifically binds to human CD69 also binds to mouse CD69 (preferably extracellular domain of mouse CD69) by antigen-antibody reaction.
  • the antibody of the present invention having cross-reactivity with mouse CD69 is superior in that it can evaluate efficacy even in mouse not expressing human CD69.
  • the antibody of the present invention having cross-reactivity with mouse CD69 binds to human CD69 at an epitope containing the amino acid sequence shown by SEQ ID NO: 33 (YNCPG).
  • the epitope containing the amino acid sequence shown in SEQ ID NO: 33 includes, for example, an epitope consisting of a continuous partial sequence of the amino acid sequence shown in SEQ ID NO: 30, which contains the amino acid sequence shown in SEQ ID NO: 33, and has an amino acid length of 12 or less.
  • an epitope consisting of the amino acid sequence shown by SEQ ID NO: 35, and an epitope consisting of the amino acid sequence shown by SEQ ID NO: 36 can be mentioned.
  • an antibody comprising a light chain variable region and a heavy chain variable region wherein the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 9, 19 or 20, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 10, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 11 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 12; and (2) an antibody comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 9, 19 or 20, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 10, CDR2 comprising the
  • the antibody described in the above-mentioned (1) or (2) can bind to human CD69 at an epitope comprising the amino acid sequence shown by SEQ ID NO: 33 (preferably, an epitope consisting of a continuous partial sequence of the amino acid sequence shown in SEQ ID NO: 30, which contains the amino acid sequence shown in SEQ ID NO: 33, and has an amino acid length of 12 or less; more preferably, epitope consisting of the amino acid sequence shown by SEQ ID NO: 35 or SEQ ID NO: 36).
  • the antibody of the present invention binds to human CD69 at an epitope consisting of the amino acid sequence shown by SEQ ID NO: 59.
  • the antibody of the present invention binds to human CD69 at an epitope containing the amino acid sequence shown by SEQ ID NO: 78 (YAGREE).
  • the epitope containing the amino acid sequence shown in SEQ ID NO: 78 includes, for example, an epitope consisting of a continuous partial sequence of the amino acid sequence shown in SEQ ID NO: 30, which contains the amino acid sequence shown in SEQ ID NO: 78, and has an amino acid length of 12 or less.
  • an epitope consisting of the amino acid sequence shown by SEQ ID NO: 57 an epitope consisting of the amino acid sequence shown by SEQ ID NO: 58 and an epitope consisting of the amino acid sequence shown by SEQ ID NO: 59 can be mentioned.
  • the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 2 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 4, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 5 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 6; (4) an antibody comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 13, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 14 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 15, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 16, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 16, CDR2 comprising the amino acid sequence shown in SEQ ID NO
  • the antibody described in the above-mentioned (3) or (5) can bind to human CD69 at an epitope consisting of the amino acid sequence shown by SEQ ID NO: 59.
  • the antibody described in the above-mentioned (4) or (6) can bind to human CD69 at an epitope consisting of the amino acid sequence shown by SEQ ID NO: 78 (preferably, an epitope consisting of a continuous partial sequence of the amino acid sequence shown in SEQ ID NO: 30, which contains the amino acid sequence shown in SEQ ID NO: 78, and has an amino acid length of 12 or less; more preferably, an epitope consisting of the amino acid sequence shown by SEQ ID NO: 57, SEQ ID NO: 58 or SEQ ID NO: 59).
  • the K D value of the antibody described in (1) relating to the binding affinity to human CD69 is preferably not more than 3 ⁇ 10 ⁇ 8 M.
  • the K D value of the antibody relating to the binding affinity to human CD69 is preferably not more than 1 ⁇ 10 ⁇ 8 M, more preferably not more than 5 ⁇ 10 ⁇ 9 M, further preferably not more than 2 ⁇ 10 ⁇ 9 M.
  • the K D value of the antibody relating to the binding affinity to human CD69 is preferably not more than 1 ⁇ 10 ⁇ 8 M, more preferably not more than 5 ⁇ 10 ⁇ 9 M, further preferably not more than 3 ⁇ 10 ⁇ 9 M.
  • the K D value of the antibody described in (2) relating to the binding affinity to human CD69 is preferably not more than 3 ⁇ 10 ⁇ 8 M.
  • the antibody described in (2) is an antibody comprising a light chain variable region and a heavy chain variable region, wherein
  • the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 19, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 10, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 11 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, except that 1 to 3 amino acids are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 7, 8 and 19, and/or 1 to 3 amino acids are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 12, the K D value of the antibody relating to the binding affinity to human CD69 is preferably not more than 1 ⁇ 10 ⁇ 8 M, more preferably not more than 5 ⁇ 10 ⁇
  • the antibody described in (2) is an antibody comprising a light chain variable region and a heavy chain variable region, wherein
  • the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 20, and the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 10, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 11 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, except that 1 to 3 amino acids are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 7, 8 and 20, and/or 1 to 3 amino acids are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NOs: 10-12, the K D value relating to the binding affinity of the antibody to human CD69 is preferably not more than 1 ⁇ 10 ⁇ 8 M, more preferably not more than
  • the K D value of the antibody described in (3) or (5) relating to the binding affinity to human CD69 is preferably not more than 5 ⁇ 10 ⁇ 8 M.
  • the K D value of the antibody described in (4) or (6) relating to the binding affinity to human CD69 is preferably not more than 8 ⁇ 10 ⁇ 9 M.
  • the number of amino acids to be substituted, deleted, inserted and/or added is not particularly limited as long as the antibody specifically binds to human CD69, and has an activity to suppress allergic inflammation. It is preferably within 2 amino acids, more preferably one amino acid, per one CDR sequence. While the number of CDR sequences in which amino acid is substituted, deleted, inserted and/or added is not particularly limited as long as the antibody specifically binds to human CD69, and has an activity to suppress allergic inflammation. It is preferably within 2, more preferably one, per one light chain variable region, and preferably within 2, more preferably 1, per one heavy chain variable region.
  • the substitution, deletion, insertion and/or addition of amino acid may be performed in both the light chain variable region and the heavy chain variable region, or either one of them.
  • 1-3 (preferably 1 or 2, more preferably 1) amino acids are preferably substituted, deleted, inserted, and/or added only in the amino acid sequence of CDR3 in the light chain variable region.
  • the amino acid sequence of the CDR3 when 1 to 3 amino acids are substituted, deleted, inserted and/or added in the amino acid sequence of CDR3 in the light chain variable region, it is preferable to maintain serine of the 2nd and tyrosine of the 3rd of the amino acid sequence of the CDR3.
  • the first amino acid of the amino acid sequence of the CDR3 is mutually substitutable between glutamine and glycine.
  • the 4th amino acid of the amino acid sequence of the CDR3 is mutually substitutable between aspartic acid and threonine.
  • the 5th amino acid of the amino acid sequence of the CDR3 is mutually substitutable between serine and threonine.
  • Examples of the method for substituting one or plural amino acid residues with other desired amino acid include site-directed mutagenesis method (Hashimoto-Gotoh, T, Mizuno, T, Ogasahara, Y, and Nakagawa, M. (1995) An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis. Gene 152, 271-275; Zoller, M J, and Smith, M. (1983) Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. Methods Enzymol.
  • an amino acid in a framework or CDR can also be substituted by other appropriate amino acid.
  • FR framework region
  • FR to be used for the antibody of the present invention is not particularly limited and any FR can be used, FR of a human antibody is preferably used.
  • the FR of a human antibody one having a natural sequence may be used, or one or plural amino acids in the framework region having a natural sequence may be substituted, deleted, added and/or inserted and the like as necessary, so that CDR will form an appropriate antigen binding site.
  • a mutant FR sequence having desired properties can be selected by measuring and evaluating the binding activity of an antibody having FR with substituted amino acid to an antigen (Sato, K. et al., Cancer Res. (1993)53, 851-856).
  • FR of V13 (Kabat database) of human antibody is preferably used for the light chain
  • FR of VH3 (Kabat database) of human antibody is preferably used for the heavy chain.
  • FR of Vk1 (Kabat database) of human antibody is preferably used for the light chain
  • FR of VH1B (Kabat database) of human antibody is preferably used for the heavy chain.
  • FR of Vk3 (Kabat database) of human antibody is preferably used for the light chain
  • FR of VH3 (Kabat database) of human antibody is preferably used for the heavy chain.
  • the constant region used for the antibody of the present invention is not particularly limited, and any constant region may be used.
  • the constant region used for the antibody of the present invention include constant regions of human antibody (constant regions derived from IgG1, IgG2, IgG3, IgG4, IgA, IgM and the like).
  • C ⁇ 1, C ⁇ 2, C ⁇ 3, C ⁇ 4, C ⁇ , C ⁇ , C ⁇ 1, C ⁇ 2, C ⁇ can be used in H chain
  • C ⁇ , C ⁇ can be used in L chain.
  • the constant region of C ⁇ of human antibody is preferably used for the light chain, and the constant region of C ⁇ 4 of human antibody is preferably used for the heavy chain.
  • the constant region of C ⁇ of human antibody is preferably used for the light chain, and the constant region of C ⁇ 4 of human antibody is preferably used for the heavy chain.
  • the constant region of C ⁇ of human antibody is preferably used for the light chain, and the constant region of C ⁇ 4 of human antibody is preferably used for the heavy chain.
  • Preferable antibody of the present invention includes the following:
  • the antibody of the above-mentioned (1′) corresponds to a preferable embodiment of the antibody of the above-mentioned (1)
  • the antibody of the above-mentioned (3′) corresponds to a preferable embodiment of the antibody of the above-mentioned (3)
  • the antibody of the above-mentioned (4′) corresponds to a preferable embodiment of the antibody of the above-mentioned (4), respectively.
  • the antibody described in the above-mentioned (1′) can bind to human CD69 at an epitope comprising the amino acid sequence shown by SEQ ID NO: 33 (preferably, an epitope consisting of a continuous partial sequence of the amino acid sequence shown in SEQ ID NO: 30, which contains the amino acid sequence shown in SEQ ID NO: 33, and has an amino acid length of 12 or less; more preferably, epitope consisting of the amino acid sequence shown by SEQ ID NO: 35 or SEQ ID NO: 36).
  • the antibody described in the above-mentioned (3′) can bind to human CD69 at an epitope consisting of the amino acid sequence shown by SEQ ID NO: 59.
  • the antibody described in the above-mentioned (4′) can bind to human CD69 at an epitope comprising the amino acid sequence shown by SEQ ID NO: 78 (preferably, an epitope consisting of a continuous partial sequence of the amino acid sequence shown in SEQ ID NO: 30, which contains the amino acid sequence shown in SEQ ID NO: 78, and has an amino acid length of 12 or less; more preferably, an epitope consisting of the amino acid sequence shown by SEQ ID NO: 57, SEQ ID NO: 58 or SEQ ID NO: 59).
  • the present invention provides a polynucleotide containing a nucleotide sequence encoding the above-mentioned antibody of the present invention.
  • the polynucleotide may be a DNA or RNA, or a DNA/RNA chimera.
  • the polynucleotide may be double stranded or single stranded. When the polynucleotide is double stranded, it may be a double stranded DNA, a double stranded RNA or a DNA:RNA hybrid.
  • the polynucleotide of the present invention encompasses a polynucleotide containing a nucleotide sequence encoding both the heavy chain variable region and the light chain variable region of the antibody of the present invention, and a combination of a polynucleotide containing a nucleotide sequence encoding the heavy chain variable region of the antibody of the present invention and a polynucleotide containing a nucleotide sequence encoding the light chain variable region of the antibody of the present invention.
  • the polynucleotide of the present invention can be easily produced based on the information of the amino acid sequence of the antibody of the present invention, known sequence information and sequence information described in the Sequence Listing in the present specification, and by utilizing known gene recombination techniques.
  • suitable primers are designed based on the sequence information
  • a DNA encoding the elements constituting the antibody of the present invention is amplified by the PCR reaction
  • DNA fragments are ligated by appropriate enzymes such as ligase and the like, whereby the polynucleotide of the present invention can be produced.
  • a polynucleotide encoding each element may be synthesized by a polynucleotide synthesizer, based on the information of the amino acid sequence of the antibody of the present invention.
  • the obtained polynucleotide encoding the antibody of the present invention may be, depending on the object, directly used, or used after digestion with a restriction enzyme when desired, or addition of a linker.
  • the polynucleotide may have ATG as a translation initiation codon on the 5′ terminal side, and may have TAA, TGA or TAG as a translation stop codon on the 3′ terminal side. These translation initiation codon and translation stop codon can be added using a suitable synthesized DNA adapter.
  • the polynucleotide of the present invention is preferably isolated or purified.
  • the isolated or purified polynucleotide of the present invention has a purity (ratio of the weight of the polynucleotide of the present invention to the total polynucleotide weight) of generally 50% or more, preferably 70% or more, more preferably 90% or more, most preferably 95% or more (e.g., substantially 100%).
  • the present invention provides a vector comprising the above-mentioned polynucleotide of the present invention.
  • the vector of the present invention encompasses a vector comprising a polynucleotide comprising a nucleotide sequence encoding both the heavy chain variable region and the light chain variable region of the antibody of the present invention, and a combination of a vector comprising a polynucleotide comprising a nucleotide sequence encoding the heavy chain variable region of the antibody of the present invention and a vector comprising a polynucleotide comprising a nucleotide sequence encoding the light chain variable region of the antibody of the present invention.
  • the vector is preferably isolated or purified.
  • the vector examples include expression vector, cloning vector and the like, which can be selected according to the object.
  • the vector is an expression vector.
  • the expression vector can express the antibody of the present invention.
  • the expression vector can be produced by operably linking the polynucleotide of the present invention to the downstream of a promoter in a suitable expression vector.
  • the kind of the vector includes, for example, plasmid vector, virus vector and the like, which can be appropriately selected according to the host to be used.
  • the genus Escherichia Escherichia coli etc.
  • the genus Bacillus Bacillus subtilis etc.
  • yeast Saccharomyces cerevisiae etc.
  • insect cell established cell line derived from larva of Mamestra brassicae ( Spodoptera frugiperda cell; Sfcell) etc.
  • insect insect (larva of Bombyx mori etc.)
  • mammalian cells rat nerve cell, monkey cell (COS-7 etc.
  • COS-7 etc. Chinese hamster cell (CHO cell etc.) etc.
  • Examples of the mammal include, but are not limited to, experiment animals such as rodents such as mouse, rat, hamster and guinea pig and the like, rabbit and the like, domestic animals such as swine, bovine, goat, horse, sheep, mink and the like, companion animals such as dog, cat and the like, primates such as human, monkey, Macaca fascicularis, Macaca mulatta , marmoset, orangutan, chimpanzee and the like, and the like.
  • experiment animals such as rodents such as mouse, rat, hamster and guinea pig and the like, rabbit and the like, domestic animals such as swine, bovine, goat, horse, sheep, mink and the like, companion animals such as dog, cat and the like, primates such as human, monkey, Macaca fascicularis, Macaca mulatta , marmoset, orangutan, chimpanzee and the like, and the like.
  • plasmid vectors examples include plasmid vectors derived from Escherichia coli (e.g., pBR322, pBR325, pUC12, pUC13), plasmid vectors derived from Bacillus subtilis (e.g., pUB110, pTP5, pC194), plasmid vectors derived from yeast (e.g., pSH19, pSH15) and the like, which can be appropriately selected according to the kind of the host to be used and the object of use.
  • Escherichia coli e.g., pBR322, pBR325, pUC12, pUC13
  • Bacillus subtilis e.g., pUB110, pTP5, pC194
  • yeast e.g., pSH19, pSH15
  • the kind of the virus vector can be appropriately selected according to the kind of the host to be used and object of use.
  • baculovirus vector and the like can be used.
  • retrovirus vectors such as moloney murine leukemia virus vector, lentivirus vector, Sindbis virus vector and the like, adenovirus vector, herpes virus vector, adeno-associated virus vector, parvovirus vector, vaccinia virus vector, sendai virus vector and the like can be used.
  • the promoter can be selected according to the kind of the host to be used, and one capable of initiating transcription in the host can be selected. For example, when the host is the genus Escherichia , trp promoter, lac promoter, T7 promoter and the like are preferable. When the host is the genus Bacillus , SPO1 promoter, SPO2 promoter, penP promoter and the like are preferable. When the host is yeast, PHO5 promoter, PGK promoter and the like are preferable. When the host is an insect cell, polyhedrin promoter, P10 promoter and the like are preferable. When the host is a mammalian cell, subgenomic (26S) promoter, CMV promoter, SR ⁇ promoter and the like are preferable.
  • 26S subgenomic
  • the vector of the present invention may contain a signal sequence for antibody secretion.
  • a signal sequence for antibody secretion when it is produced in the periplasm of Escherichia coli , pelB signal sequence (Lei, S. P. et al J. Bacteriol. (1987) 169, 4379) may be used.
  • the vector of the present invention may contain enhancer, splicing signal, polyA addition signal, selection marker, SV40 replication origin (hereinafter iv sometimes to be abbreviated as SV40ori) and the like each in an operable manner.
  • the selection marker include dihydrofolate reductase (hereinafter sometimes to be abbreviated as dhfr) gene [methotrexate (MTX) resistance], ampicillin resistance gene (sometimes to be abbreviated as Amp r ), neomycin resistance gene (sometimes to be abbreviated as Neo r , G418 resistance) and the like.
  • a transformant with the vector introduced thereinto can be produced.
  • the transformant can express the antibody of the present invention.
  • the transformant of the present invention is useful for the production of the antibody of the present invention and the like.
  • the antibody of the present invention can be produced by culturing the transformant of the present invention by a method known per se according to the kind of the host, and isolating the antibody of the present invention from the culture.
  • the transformant is cultured in an appropriate medium such as LB medium, M9 medium and the like at generally about 15-43° C. for about 3-24 hr.
  • the transformant is cultured in an appropriate medium generally at about 30-40° C. for about 6-24 hr.
  • the host is yeast
  • the transformant is cultured in an appropriate medium such as Burkholder's medium and the like generally at about 20° C.-35° C. for about 24-72 hr.
  • the transformant When the host is an insect cell or insect, the transformant is cultured in an appropriate medium such as Grace's Insect medium added with about 10% of bovine serum and the like generally at about 27° C. for about 3-5 days. When the host is an animal cell, the transformant is cultured in an appropriate medium such as MEM medium added with about 10% of bovine serum and the like generally at about 30° C.-40° C. for about 15-60 hr. In any culture, aeration and stirring may be performed as necessary.
  • an appropriate medium such as Grace's Insect medium added with about 10% of bovine serum and the like generally at about 27° C. for about 3-5 days.
  • the transformant When the host is an animal cell, the transformant is cultured in an appropriate medium such as MEM medium added with about 10% of bovine serum and the like generally at about 30° C.-40° C. for about 15-60 hr. In any culture, aeration and stirring may be performed as necessary.
  • the separation and purification of the antibody of the present invention from a culture is not limited in any manner, and the separation and purification methods generally used for purification of antibody can be employed.
  • antibody can be separated and purified by appropriately selecting and combining chromatography column, filter, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization and the like.
  • chromatography examples include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gelfiltration, reversed-phase chromatography, adsorption chromatography and the like (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographys can be performed by using liquid phase chromatography, for example, liquid phase chromatography such as HPLC, FPLC and the like.
  • column to be used for affinity chromatography include protein A column and protein G column. For example, as a column using protein A, Hyper D, POROS, Sepharose FF (manufactured by GE Amersham Biosciences) and the like can be mentioned.
  • the present invention also encompasses an antibody highly purified by these purification methods.
  • the present invention provides a pharmaceutical composition containing the above-mentioned antibody of the present invention as an active ingredient.
  • the pharmaceutical composition of the present invention can also be used for the prophylaxis or treatment of allergic diseases and inflammatory diseases involving human CD69. That is, the present invention also provides a prophylactic agent or a therapeutic agent for allergic diseases or inflammatory diseases, which contains the aforementioned antibody as an active ingredient.
  • the allergic disease include, but are not limited to, allergic asthma, allergic rhinitis, pollinosis, atopic dermatitis, urticaria, food allergy, allergic conjunctivitis, and the like.
  • inflammatory disease examples include, but are not limited to, chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, interstitial pneumonia, lung fibrosis, lung edema, adult respiratory distress syndrome, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion damage, chronic glomerulonephritis, endotoxin shock, osteoarthritis, multiple sclerosis and the like.
  • COPD chronic obstructive pulmonary disease
  • emphysema bronchitis
  • interstitial pneumonia examples include, but are not limited to, chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, interstitial pneumonia, lung fibrosis, lung edema, adult respiratory distress syndrome, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion damage, chronic glomeruloneph
  • Examples of the allergic disease in the respiratory organs include, but are not limited to, allergic asthma and the like.
  • Examples of the inflammatory disease in the respiratory organs include, but are not limited to, chronic obstructive pulmonary disease (COPD), emphysema, bronchitis, interstitial pneumonia, lung fibrosis, lung edema, adult respiratory distress syndrome and the like.
  • COPD chronic obstructive pulmonary disease
  • the antibody of the present invention is “contained as an active ingredient”, it means that the antibody of the present invention is contained as at least one of the active ingredients, and does not limit the content thereof.
  • the pharmaceutical composition of the present invention may contain other active ingredient(s) together with the antibody of the present invention.
  • the antibody of the present invention can be formulated according to a conventional method (e.g., Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, U.S.A). Where necessary, moreover, it may contain a pharmaceutically acceptable carrier and/or additive. For example, it can contain surfactant (PEG, Tween etc.), excipient, antioxidant (ascorbic acid etc.), colorant, flavor, preservative, stabilizer, buffering agent (phosphate, citrate, other organic acid etc.), chelating agent (EDTA etc.), suspending agent, isotonizing agent, binder, disintegrant, lubricant, glidant, corrigent and the like. Not being limited to these, the pharmaceutical composition of the present invention may contain other conventional carriers as appropriate.
  • a pharmaceutically acceptable carrier and/or additive can contain surfactant (PEG, Tween etc.), excipient, antioxidant (ascorbic acid etc.), colorant, flavor, preservative, stabilizer, buffering agent (phosphate, citrate
  • Specific examples include light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl acetaldiethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain fatty acid triglyceride, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, cornstarch, inorganic salts and the like. It may also contain other low-molecular-weight polypeptide, serum albumin, gelatin and protein such as immunoglobulin and the like, as well as amino acid.
  • the antibody of the present invention is dissolved in, for example, isotonic solution containing saline, glucose or other auxiliary agent.
  • auxiliary agent include D-sorbitol, D-mannose, D-mannitol, and sodium chloride, and may be used in combination with suitable solubilizing agents, for example, alcohol (ethanol etc.), polyalcohol (propylene glycol, PEG etc.), non-ionic surfactant (polysorbate 80, HCO-50) and the like.
  • polypeptide may also be included in a microcapsule (microcapsules made of hydroxymethylcellulose, gelatin, poly[methylmethacrylate] and the like), or formulated as a colloid drug delivery system (liposome, albumin microsphere, microemulsion, nanoparticles and nanocapsule etc.) (see Remington's Pharmaceutical Science 16th edition &, Oslo Ed. (1980) etc.).
  • a method of formulating a drug as a sustained-release medicament is also known, and applicable to polypeptide (Langer et al., J. Biomed. Mater. Res. (1981)15: 167-277; Langer, Chem. Tech. (1982)12: 98-105; U.S. Pat. No.
  • the content of the antibody of the present invention in a pharmaceutical composition is, for example, about 0.01-100 wt %, preferably 0.1-99.9 wt %, of the whole pharmaceutical composition.
  • the pharmaceutical composition of the present invention can be administered both orally and parenterally, it is preferably administered parenterally. Specifically, it is administered to patients by injection or transdermal administration.
  • the dosage form of injection it can be administered systemically or topically by intravenously injection, intramuscular injection, subcutaneous injection and the like. It may also be administered to the treatment site or in the vicinity thereof by topical injection, particularly intramuscular injection.
  • Examples of the dosage form of transdermal administration include ointment, gel, cream, plaster, patch and the like, which can be administered systemically or topically.
  • the administration method can be appropriately selected according to the age and symptom of the patients.
  • the dose can be selected from, for example, the range of 0.5 mg-2.5 mg/kg body weight as the antibody of the present invention.
  • the pharmaceutical composition of the present invention is not limited by these doses.
  • the present invention provides a non-human mammal useful for the analysis of the function of human CD69 in allergic diseases, inflammatory diseases and the like. Specifically, the present invention provides a non-human mammal comprising a transferred Th2 cells of CD69 deficient non-human mammal immunized with a particular antigen, which express human CD69.
  • non-human mammal examples include experiment animals such as mouse, rat, hamster, guinea pig, rabbit and the like, domestic animals such as swine, bovine, goat, horse, sheep and the like, pets such as dog, cat and the like, primates such as monkey, orangutan, chimpanzee and the like.
  • the non-human mammal is preferably mouse.
  • the genotype of the CD69 deficient non-human mammal, from which the Th2 cells are derived may be immunologically self (i.e., syngenic) or immunologically nonself (i.e., allogeneic or xenogeneic) to the animal species of the non-human mammal of the present invention. Since the transferred Th2 cells are engrafted in the body for a long term, it is preferably immunologically self.
  • CD69 deficient refers to the state where sufficient operation of the normal function that CD69 gene intrinsically has is prevented. Examples thereof include a complete absence of the expression of CD69 gene, a decreased expression level at which the normal function that CD69 gene intrinsically has cannot be exhibited sufficiently, complete loss of the function of CD69 gene product, and a decreased function of CD69 gene product at which the normal function that CD69 gene intrinsically has cannot be exhibited.
  • the CD69 deficient non-human mammal is preferably an animal accompanying modification of genome DNA, i.e., transgenic animal.
  • the CD69 deficient non-human mammal may be CD69 gene deficient heterozygote, or CD69 gene deficient homozygote, preferably CD69 gene deficient homozygote.
  • a CD69 deficient non-human mammal can be obtained by, for example, transfecting ES cells with a targeting vector inducing homologous recombination of CD69 gene to prepare ES cells introduced with deficiency in one of the alleles of CD69 gene, preparing, from the obtained ES cells, offspring animals introduced with deficiency in one of the alleles of CD69 gene derived therefrom, and crossing the offspring animals.
  • a targeting vector inducing homologous recombination of CD69 gene to prepare ES cells introduced with deficiency in one of the alleles of CD69 gene, preparing, from the obtained ES cells, offspring animals introduced with deficiency in one of the alleles of CD69 gene derived therefrom, and crossing the offspring animals.
  • the kind of the antigen is not particularly limited as long as it has antigenicity to the CD69 deficient non-human mammal, and a desired antigen can be selected.
  • the antigen include protein, peptide, lipid, sugar chain and the like having antigenicity to the CD69 deficient non-human mammal.
  • the CD69 deficient non-human mammal can be immunized with an antigen by injecting the antigen in an amount sufficient for immunizing the CD69 deficient non-human mammal.
  • the CD69 deficient non-human mammal is immunized with the antigen at a frequency of once in 1-3 weeks, 2-6 times in total.
  • the antigen may be administered together with an adjuvant to the CD69 deficient non-human mammal.
  • the adjuvant is not particularly limited as long as it can enhance immunogenicity, for example, aluminum hydroxide, keyhole limpet hemocyanin, dextran, BCG, aluminum phosphate, TLR ligand (e.g., lipopolysaccharide (LPS), CpG) and the like can be mentioned.
  • Aluminum hydroxide and the like are preferably used for efficient induction of Th2 cells.
  • Th2 cell refers to a CD4T cell which is differentiated from na ⁇ ve CD4T cells by antigen stimulation, and predominantly producing IL-4.
  • Th2 cells can be obtained by, for example, isolating CD4T cells from the spleen or peripheral blood of a CD69 deficient non-human mammal immunized with a particular antigen, and cultivating the CD4T cells in the presence of the antigen, antigen presenting cells, IL-2 and IL-4.
  • An immobilized anti-TCR antibody or anti-CD3 antibody may also be used instead of the antigen.
  • Th2 cells can be induced more potently by using an immobilized anti-CD28 antibody in combination.
  • Th2 cells Whether the obtained cells are Th2 cells can be confirmed by stimulating the obtained cells with the antigen, and evaluating whether it predominantly produces IL-4 as compared to IFN- ⁇ by flow cytometry.
  • Th2 cells of the CD69 deficient non-human mammal are transfected with an expression vector capable of expressing human CD69 in Th2 cells of the non-human mammal.
  • an expression vector capable of expressing human CD69 in Th2 cells of the non-human mammal.
  • the vector plasmid vector, virus vector, retrovirus vector and the like can be mentioned.
  • retrovirus vector is preferably used in the present invention.
  • the expression of human CD69 in Th2 cell can be confirmed by flow cytometry using an anti-human CD69 antibody.
  • Th2 cells of a CD69 deficient non-human mammal immunized with a particular antigen, that express human CD69 can be transferred into a recipient non-human mammal by intravenously or intraperitoneally injecting the Th2 cells to the recipient non-human mammal.
  • the number of the Th2 cells to be transferred is not particularly limited as long as the response reaction of the transferred Th2 cells to said antigen can be observed in the recipient non-human mammal.
  • the recipient non-human mammal is a mouse, for example, 1,000,000-3,000,000 Th2 cells are preferably transferred.
  • the transferred Th2 cells are activated by stimulation with the particular antigen to produce a large amount of IL-4. Therefore, when the non-human mammal of the present invention is exposed to said antigen, an allergic reaction mediated by the Th2 cells expressing human CD69 and an inflammation reaction associated therewith occur.
  • the present invention also provides such non-human mammal allergy model. Using the non-human mammal of the present invention, the role of human CD69 in allergic reactions and inflammation reactions can be easily analyzed in vivo. In addition, efficacy evaluation of an anti-human CD69 antibody for allergic diseases and inflammatory diseases can be performed in non-human mammals.
  • lysis buffer 200 mM borate, 160 mM NaCl, 2 mM EDTA, 1 mg/ml lysozyme, pH 8.0
  • human CD69 homodimer protein was purified according to the standard method of Strep-Tactin column (manufactured by IBA). In addition, the purity of the purified human CD69 recombinant protein was confirmed to be not less than 95% by SDS-PAGE, and the protein concentration was determined by using BCA Protein Assay Kit (manufactured by PIERCE).
  • the purified human CD69 recombinant protein was biotinylated according to the standard protocol of EZ-Link NHS-PEO 4 -Biotin (Thermo Scientific), and the concentration was determined by using BCA Protein Assay Kit (manufactured by PIERCE).
  • the biotinylated human CD69 recombinant protein was immobilized on streptavidin-coated magnetic beads (Dynabeads MyOne Streptavidin T1 magnetic beads, manufactured by Invitrogen, 100 ⁇ l) at 4° C. for 1 hr, and washed 5 times with 1 ml PEST (PBS containing 0.05% Tween 20).
  • HuCAL GOLD manufactured by MorphoSys
  • Human CD69-immobilized beads were added to the phage library to bind an antigen-specific antibody.
  • the magnetic beads were recovered and washed several times, and the phage was eluted from the magnetic beads.
  • Escherichia coli cells were infected with the eluted phage and cultured at 37° C. overnight.
  • An operation of phage-rescue from the phage-infected Escherichia coli cells followed a general method (Molecular cloning third. Ed. Cold Spring Harbor Lab. Press, 2001).
  • the selection round described above was repeated several times to concentrate a phage presenting an antibody specific to the antigen.
  • the pool of Fab genes obtained after the concentration operation was subcloned to Escherichia coli expression vector. According to the method described in WO 2006/122797 and the like, the Fab antibody was expressed, and the antigen-specific antibody was screened for by the ELISA method.
  • the Fab antibody was purified from a soluble fraction of Escherichia coli lysate according to the standard method of Strep-Tactin column (manufactured by IBA). In addition, the purity of the purified antibody was confirmed by SDS-PAGE, and the concentration was determined by using BCA Protein Assay Kit (manufactured by PIERCE).
  • the purified ELISA-positive Fab antibody clones were further evaluated for antigen reactivity by cell staining of human CD69 and mouse CD69 over-expressing cells.
  • As the antigen CHO-S cells fixed with 4% PFA 48 hr after the transfection with human CD69 or mouse CD69 expression vector by the standard method using FreeStyle MAX Reagent (manufactured by Invitrogen) were used. With 50 ⁇ g/ml purified Fab antibody as the primary antibody for staining, cells were incubated at room temperature for 1 hr, and washed 3 times with PBS.
  • the obtained three clones (160-c7, 160-c76 and 160-c103) of Escherichia coli were cultured, and plasmids were recovered (QIAprep Spin MiniPrep kit: manufactured by QIAGEN) and used for the base sequence analysis.
  • Table 1 shows the amino acid sequences of CDRs (complementarity determining regions) of the respective clones.
  • IgG expression vectors constant region of heavy chain was IgG4.
  • HEK293T cells were transfected with these expression vectors according to the standard method of Lipofectamine (manufactured by Invitrogen), and the culture supernatant after culture for 72 hr was recovered.
  • DMEM Stemcell
  • Ultra Low IgG FBS manufactured by Invitrogen
  • IgG antibody was purified by the standard method using rProteinA Sepharose Fast Flow (manufactured by GE healthcare). Protein after purification was confirmed to show a single band by SDS-PAGE, and the concentration was determined by using BCA Protein Assay Kit (manufactured by PIERCE).
  • mice obtained by crossing BALB/c mouse or CD69 deficient (CD69KO) mouse back-crossed not less than 10 times onto BALB/c (Murata, K. et al. 2003. Int. Immunol. 15: 987-992) with D011.10 transgenic mouse were used.
  • the spleen CD4T cells of these mice were purified by AutoMACS sorter (Miltenyi Biotec) to a purity of >98%.
  • the isolated CD4T cells were cultured with stimulation with immobilized anti-TCR and anti-CD28 monoclonal antibodies under Th2 conditions (IL-2 10 u/ml, IL-4 100 U/ml).
  • human CD69 gene was introduced by a retrovirus vector containing human CD69 (hCD69) gene.
  • the method of introducing human CD69 gene followed the method described previously (Kimura, M. et al. 2001. Immunity 15: 275-287).
  • Five days after the start of the culture the cultured cells were recovered, and the expression of human CD69 was confirmed by flow cytometry ( FIG. 2 ). 50.2% of the cells were human CD69 positive.
  • CD69 KO mouse Th2 cells that overexpress human CD69 (hCD69) obtained by the above-mentioned culture, or wild-type BALB/c mouse Th2 cells were intravenously injected into wild-type BALB/c mice (day 0). After cell transfer, on day 1 and day 3, the mice were exposed to allergen challenge via airway by inhaling 1% OVA solution in aerosolized saline for 30 min using an ultrasonication nebulizer (NE-U07; manufactured by Omron).
  • NE-U07 ultrasonication nebulizer
  • BAL bronchoalveolar lavage
  • the results are shown in FIG. 3 .
  • the anti-hCD69 antibodies suppressed intraalveolar infiltration of mononuclear cells, particularly infiltration of eosinophils, which is caused by OVA inhalation.
  • the antibody selection round was repeated twice, the base sequences of the light chain CDR3 of the obtained antibody clones were examined and antibody clones having a novel sequence were identified. They were expressed in Escherichia coli , and ELISA was performed for the antigen by using the lysate and the amount of the antibody in the lysate was simultaneously measured by sandwich ELISA. The relative specific binding activity of each clone was calculated from the absorbance of ELISA against the antigen and the antibody amount, and high affinity clones were selected. In addition, IgG of top 10 clones having high affinity were prepared and K D values were measured.
  • Fab antibody gene was subcloned to construct IgG expression vector (constant region of heavy chain was IgG4).
  • HEK293T cells were transfected with the expression vector by Lipofectamine (manufactured by Invitorogen), cultured for 72 hr, and IgG antibody was purified from the recovered culture supernatant.
  • the affinity of the prepared IgG clones for human CD69 was evaluated by scatchard plot. To be specific, it was calculated according to the principle described in Immunoassays (OXFORD UNIVERSITY PRESS, 2000). An antibody was incubated with various concentrations of antigen at room temperature for 2 hr until it reaches equilibrium, and the amount of free antibody present in the incubation liquids was measured by the ELISA method. The binding constant and dissociation constant (K D value) were determined based on the changes in the amount of free antibody in each equilibrate sample. The concentration of the antibody in the equilibration reaction was set to 0.015 ⁇ g/ml, and an ELISA plate immobilized with the antigen at 1 ⁇ g/ml was used for the measurement of the amount of free antibody.
  • mouse CD69 The reactivity with mouse CD69 was evaluated as follows. Splenocytes were isolated from wild-type mouse and CD69 KO mouse (both Balb/c), and stimulated with Phorbol 12-myristate 13-acetate (PMA) for 4 hr to induce expression of CD69 on the cell surface. Each anti-human CD69 antibody (160-c76, 234-61 and 234-83) (1 ⁇ g) was added to 1 ⁇ 10 6 splenocytes, and the mixture was incubated on ice for 30 min. The cells were washed, anti-human IgG-Alexa488 ( ⁇ 200 diluted) was added as a secondary antibody, and the mixture was incubated on ice for 20 min.
  • PMA Phorbol 12-myristate 13-acetate
  • PBMCs peripheral blood mononuclear cells
  • FN50 mouse anti-human CD69 monoclonal antibody
  • CD69 deficient mice back-crossed not less than 10 times onto BALB/c were intraperitoneally immunized with 250 ⁇ g of OVA (hen egg albumin from Sigma-Aldrich) in 4 mg of aluminum hydroxide gel (alum).
  • Spleen CD4T cells of the OVA-immunized CD69 deficient mouse were purified using CD4+T cell isolation kit manufactured by Miltenyi Biotec) and AutoMACS sorter (manufactured by Miltenyi Biotec) to a purity of >98%.
  • the isolated CD4T cells were cultured with stimulating with immobilized anti-TCR and anti-CD28 mAbs under Th2 conditions.
  • hCD69 gene was introduced by a retrovirus vector containing human CD69 (hCD69) gene. Five days after the start of the culture, the cultured cells were recovered, and the expression of hCD69 was confirmed by flow cytometry. 58.7% of the cells were hCD69 positive.
  • BAL bronchoalveolar lavage
  • a peptide array on which partial peptides of human CD69 were immobilized epitope mapping of anti-human CD69 antibodies 234-83, 160-c7 and 160-c103 was performed.
  • a peptide array consisting of peptides having the residue number of 12 amino acid residues and an offset of 3 amino acid residues was produced for a sequence covering the extracellular domain of human CD69 (60-199) (PepSpots, manufactured by JPT).
  • the peptide array and the anti-human CD69 antibody were reacted according to the manual of JPT.
  • Anti-human CD69 antibodies labeled with HRP Peroxidase Labeling Kit—NH2, manufactured by Dojindo
  • 234-83 specifically bound to the above-mentioned peptides #2 and #3, particularly strongly bound to peptide #3.
  • 160-c7 specifically bound to the above-mentioned peptide #26.
  • the results show that 160-c7 binds to human CD69 at an epitope consisting of the amino acid sequence shown in SEQ ID NO: 59.
  • 160-c103 specifically bound to the above-mentioned peptides #24, #25 and #26.
  • an anti-human CD69 antibody applicable to the prophylaxis or treatment of allergic diseases and inflammatory diseases is provided.
  • an animal model permitting in vivo evaluation of a pharmacological effect of an anti-human CD69 antibody can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US14/396,521 2012-04-23 2013-04-23 Anti-human cd69 antibody, and use thereof for medical purposes Abandoned US20150118237A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-098243 2012-04-23
JP2012098243 2012-04-23
PCT/JP2013/061918 WO2013161814A1 (ja) 2012-04-23 2013-04-23 抗ヒトｃｄ６９抗体、及びその医薬用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/061918 A-371-Of-International WO2013161814A1 (ja) 2012-04-23 2013-04-23 抗ヒトｃｄ６９抗体、及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/153,449 Continuation US20190233521A1 (en) 2012-04-23 2018-10-05 Anti-human cd69 antibody, and use thereof for medical purposes

Publications (1)

Publication Number Publication Date
US20150118237A1 true US20150118237A1 (en) 2015-04-30

Family

ID=49483123

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/396,521 Abandoned US20150118237A1 (en) 2012-04-23 2013-04-23 Anti-human cd69 antibody, and use thereof for medical purposes
US16/153,449 Abandoned US20190233521A1 (en) 2012-04-23 2018-10-05 Anti-human cd69 antibody, and use thereof for medical purposes
US16/796,481 Active US10865247B2 (en) 2012-04-23 2020-02-20 Anti-human CD69 antibody, and use thereof for medical purposes

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/153,449 Abandoned US20190233521A1 (en) 2012-04-23 2018-10-05 Anti-human cd69 antibody, and use thereof for medical purposes
US16/796,481 Active US10865247B2 (en) 2012-04-23 2020-02-20 Anti-human CD69 antibody, and use thereof for medical purposes

Country Status (8)

Country Link
US (3) US20150118237A1 (zh)
EP (1) EP2843051B1 (zh)
JP (1) JP6286757B2 (zh)
CN (1) CN104379741B (zh)
AU (1) AU2013253581B2 (zh)
CA (1) CA2871417C (zh)
WO (1) WO2013161814A1 (zh)
ZA (1) ZA201408566B (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017066136A3 (en) * 2015-10-13 2017-05-26 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
US10098951B2 (en) 2015-10-23 2018-10-16 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US11655298B2 (en) 2016-10-21 2023-05-23 Yamaguchi University Composition for treating fulminant acute pneumonia including CD69 antagonist

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
CN100335501C (zh) 1996-09-26 2007-09-05 中外制药株式会社 抗人副甲状腺激素相关蛋白的抗体
US7867475B2 (en) * 2003-01-31 2011-01-11 Universidad Autonoma De Madrid Immune regulation based on the depletion of CD69+ cells
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
PL2405015T3 (pl) 2003-03-05 2016-09-30 Rozpuszczalna glikoproteina o aktywności hialuronizady (sHASEGP), sposób jej wytwarzania, jej zastosowania i zawierające ją kompozycje farmaceutyczne
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
CA2575901C (en) * 2004-08-02 2015-01-27 Amrad Operations Pty. Ltd. A method of treating cancer comprising a vegf-b antagonist
DK1888643T3 (en) 2005-05-18 2015-01-05 Morphosys Ag Anti-GM-CSF antibodies as well as their uses
JP2007022993A (ja) * 2005-07-20 2007-02-01 Chiba Univ アレルギー性喘息の治療薬
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
US20120253017A1 (en) * 2009-05-28 2012-10-04 Victoria Ballard Stem cell targeting

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Campbell et al. 'Monoclonal Antibody Technology.', edited by R. H. Burdon, Elsevier, 1987, pp. 1-32. *
MARIUZZA, R.A. et al. 'The Structural Basis of Antigen-Antibody Recognition' Annu. Rev. Biophys. Biphys. Chem. 16:139-159, 1987 *
Rader et al. PNAS. 95:8910-8915, 1998. *
Rudikoff et al. "Single Amino Acid Substitution Altering Antigen-Binding Specificity" PNAS. 79:1979-1983, 1982. *
Ziegler et al. 'Molecular characterization of the early activation antigen CD69: a type I1 membrane glycoproteinrelated to a family of natural killer cell activation antigens.' Eur. J. Immunol. 23:1643-1648, 1993. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
IL258332B2 (en) * 2015-10-13 2023-05-01 Eureka Therapeutics Inc Antibody factors specific for human differentiation group 19 and their uses
WO2017066136A3 (en) * 2015-10-13 2017-05-26 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
IL258332A (en) * 2015-10-13 2018-05-31 Eureka Therapeutics Inc Antibody factors specific for human differentiation group 19 and their uses
US10301388B2 (en) 2015-10-13 2019-05-28 Eureka Therapeutics, Inc. Antibody agents specific for human CD19 and uses thereof
US11981742B2 (en) 2015-10-13 2024-05-14 Eureka Therapeutics, Inc. Antibody agents specific for human CD19 and uses thereof
US10098951B2 (en) 2015-10-23 2018-10-16 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US11421013B2 (en) 2015-10-23 2022-08-23 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US10822389B2 (en) 2015-10-23 2020-11-03 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US11976105B2 (en) 2015-10-23 2024-05-07 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US10464988B2 (en) 2015-10-23 2019-11-05 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US11655298B2 (en) 2016-10-21 2023-05-23 Yamaguchi University Composition for treating fulminant acute pneumonia including CD69 antagonist
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US11965021B2 (en) 2017-04-26 2024-04-23 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof

Also Published As

Publication number Publication date
EP2843051B1 (en) 2018-06-06
US20190233521A1 (en) 2019-08-01
AU2013253581A1 (en) 2014-12-04
CA2871417A1 (en) 2013-10-31
CA2871417C (en) 2021-08-31
ZA201408566B (en) 2019-03-27
EP2843051A1 (en) 2015-03-04
CN104379741A (zh) 2015-02-25
WO2013161814A1 (ja) 2013-10-31
JPWO2013161814A1 (ja) 2015-12-24
JP6286757B2 (ja) 2018-03-07
US20200199235A1 (en) 2020-06-25
AU2013253581B2 (en) 2019-05-16
CN104379741B (zh) 2021-07-20
US10865247B2 (en) 2020-12-15
EP2843051A4 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
US10865247B2 (en) Anti-human CD69 antibody, and use thereof for medical purposes
KR102256152B1 (ko) Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
RU2769352C2 (ru) Антитела и полипептиды, направленные против cd127
JP7324565B2 (ja) Ｃｄ１２７に対する抗体
KR20160101940A (ko) 인간 항 il-33 중화 단일클론 항체
BR112014009069A2 (pt) polipeptídeos de anticorpo que antagonizam cd40l
TWI791006B (zh) 包含bdnf之融合蛋白質
JP6900051B2 (ja) Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
US20140286957A1 (en) ANTIBODIES TO CD1d
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
KR20240046533A (ko) 항-ccr8 항체 및 그것의 용도
MX2014001313A (es) Nuevos anticuerpos contra fosforilcolina.
US20240084019A1 (en) Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
US11203644B2 (en) Anti-TLR9 antibody, pharmaceutical composition, and kit
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
TW202409089A (zh) １型大麻素受體結合蛋白及其用途
TW202204418A (zh) Ｐｄ－１抗原結合蛋白及其應用
CA3213285A1 (en) Bioengineered immunomodulatory fusion protein compositions
CN115724969A (zh) Lag-3结合分子及其应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENEFRONTIER CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOJOH, KANEHISA;MIYAKOSHI, AKIRA;KATOH, SHIZUE;AND OTHERS;SIGNING DATES FROM 20141008 TO 20141019;REEL/FRAME:034177/0950

Owner name: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOJOH, KANEHISA;MIYAKOSHI, AKIRA;KATOH, SHIZUE;AND OTHERS;SIGNING DATES FROM 20141008 TO 20141019;REEL/FRAME:034177/0950

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION